New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
GlaxoSmithKline PLC's severe asthma treatment Nucala will need to be significantly discounted to make it cost-effective, according to a draft report on the product's value by the Institute for Clinical and Economic Review released Dec. 21.
Nucala (mepolizumab), a physician-administered biologic approved Nov. 4, is priced at a wholesale acquisition cost (WAC) of $32,500 per year of use ([A#14151104009]). ICER regularly conducts studies of high-cost...
A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.
The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.
The Clinical Trials Access Collaborative (CTAC) will build on a pilot program's work to bolster community-based clinical research infrastructure so "anyone who wants to participate in clinical trials can and do it closer to home,” CEO Tesheia Harris said in an interview.
